MetLife Investment Management LLC Sells 49,175 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

MetLife Investment Management LLC lowered its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 57.5% during the 3rd quarter, Holdings Channel reports. The firm owned 36,287 shares of the company’s stock after selling 49,175 shares during the quarter. MetLife Investment Management LLC’s holdings in Lyell Immunopharma were worth $50,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its position in Lyell Immunopharma by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after acquiring an additional 19,287 shares in the last quarter. SG Americas Securities LLC boosted its position in Lyell Immunopharma by 78.1% during the 3rd quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock valued at $79,000 after acquiring an additional 25,247 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Lyell Immunopharma by 197.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after acquiring an additional 26,635 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in Lyell Immunopharma by 37.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company’s stock valued at $186,000 after acquiring an additional 36,715 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in Lyell Immunopharma during the 3rd quarter valued at $52,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

Lyell Immunopharma stock opened at $0.92 on Wednesday. The stock has a market capitalization of $267.39 million, a price-to-earnings ratio of -1.16 and a beta of -0.45. Lyell Immunopharma, Inc. has a 1-year low of $0.85 and a 1-year high of $3.26. The business has a fifty day moving average price of $1.08 and a 200-day moving average price of $1.48.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. The firm had revenue of $0.03 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, equities research analysts anticipate that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Bank of America cut Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their target price for the company from $6.00 to $1.00 in a research report on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Tuesday, November 12th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.